Identifying mechanism of resistance to current melanoma therapy-Neel M. Fofaria-03/31/2015 - 8:30am

Event Information
Event Topic: 
Identifying mechanism of resistance to current melanoma therapy
Event Date: 
03/31/2015 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Neel M. Fofaria
Event Speaker Title: 
PhD Candidate
Event Speaker Company: 
Texas Tech University Health Sciences Center, School of Pharmacy
Event Speaker Bio: 

Neel received his Bachelor’s in Pharmaceutical Sciences from Mumbai University. Currently, he is a PhD candidate in Pharmaceutical Sciences at Texas Tech University Health Sciences Center. His research focuses on multidisciplinary Cancer Drug Discovery and Development research involving elucidation of novel drug targets or mechanism of drug resistance and determining Novel Therapeutics and Combination Regimen. Neel authored 6 peer reviewed publications and 4 more under review or revision. He is also a co-inventor in two patents and has received a number of awards at various national conferences for his research. Neel is the current President of the Graduate Student Association at Texas Tech University and the Chair of American Association of Pharmaceutical Sciences (AAPS) – Student Chapter.

Event Details
Event Details: 

Melanoma harboring BRAF mutations frequently develop resistance to BRAF inhibitors, limiting the impact of treatment. The mechanisms of acquired resistance to BRAF V600E inhibitors appear to be unclear. Furthermore, relatively little is known about the determinants of de novo resistance. These findings provide molecular evidence for induction of resistance to BRAF inhibitors alone and in combination with MEK1/2 inhibitors and establish that combining BRAF inhibitors with Mcl-1 targeted therapeutics can overcome this resistance, thereby providing a suitable targeted therapy for the patients with late stage melanoma.